IFRX vs ARGX vs RARE vs IMVT vs PRAX

For growth investors, argenx SE (ARGX) is the stronger pick with 90.

1% revenue growth year-over-year, versus -100. 0% for Praxis Precision Medicines, Inc. (PRAX). argenx SE (ARGX) offers the better valuation at 40. 1x trailing P/E (30. 0x forward), making it the more compelling value choice. Analysts rate InflaRx N. V. (IFRX) a "Buy" — based on 15 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

Over the past 5 years, argenx SE (ARGX) delivered a total return of +198.

6%, compared to -77. 2% for Ultragenyx Pharmaceutical Inc. (RARE). Over 10 years, the gap is even starker: ARGX returned +33. 2% versus IFRX's -82. 3%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), argenx SE (ARGX) is the lower-risk stock at 0.

52β versus InflaRx N. V. 's 2. 08β — meaning IFRX is approximately 296% more volatile than ARGX relative to the S&P 500. On balance sheet safety, Praxis Precision Medicines, Inc. (PRAX) carries a lower debt/equity ratio of 0% versus 2% for InflaRx N. V. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), argenx SE (ARGX) is pulling ahead at 90.

1% versus -100. 0% for Praxis Precision Medicines, Inc. (PRAX). On earnings-per-share growth, the picture is similar: argenx SE grew EPS 53. 6% year-over-year, compared to -45. 2% for Immunovant, Inc.. Over a 3-year CAGR, ARGX leads at 116. 4% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

argenx SE (ARGX) is the more profitable company, earning 31.

1% net margin versus -1555. 8% for InflaRx N. V. — meaning it keeps 31. 1% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: ARGX leads at 23. 4% versus -1735. 9% for IFRX. At the gross margin level — before operating expenses — ARGX leads at 89. 1%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

Analyst consensus price targets imply the most upside for RARE: 97.

1% to $51. 50.

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

For long-horizon retirement investors, argenx SE (ARGX) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.

52)). InflaRx N. V. (IFRX) carries a higher beta of 2. 08 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (ARGX: +33. 2%, IFRX: -82. 3%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: IFRX is a small-cap quality compounder stock; ARGX is a mid-cap high-growth stock; RARE is a small-cap high-growth stock; IMVT is a small-cap quality compounder stock; PRAX is a small-cap quality compounder stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.